Insulin sensitivity of hepatic glucose and lipid metabolism in animal models of hepatic steatosis
Grefhorst, Aldo

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2006

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Enhanced glucose cycling and suppressed de novo synthesis of glucose-6-phosphate result in a net unchanged hepatic glucose output in ob/ob mice.
Summary

Aims/hypothesis Leptin-deficient ob/ob mice are hyperinsulinaemic and hyperglycaemic; however, the cause of hyperglycaemia remains largely unknown. Methods Glucose metabolism in vivo in 9-h fasted ob/ob mice and lean littermates was studied by infusing [U-\(^{13}\)C\]-glucose, [2-\(^{13}\)C\]-glycerol, [1-\(^{2}\)H\]-galactose and paracetamol for 6 h, applying mass isotopomer distribution analysis on blood glucose and urinary paracetamol-glucuronide. Results When expressed on the basis of body weight, endogenous glucose production (109 ± 23 vs 152 ± 27 µmol·kg\(^{-1}\)·min\(^{-1}\), obese versus lean mice, \(p<0.01\)) and de novo synthesis of glucose-6-phosphate (122 ± 13 vs 160 ± 6 µmol·kg\(^{-1}\)·min\(^{-1}\), obese versus lean mice, \(p<0.001\)) were lower in ob/ob mice than in lean littermates. In contrast, glucose cycling was greatly increased in obese mice (56 ± 13 vs 26 ± 4 µmol·kg\(^{-1}\)·min\(^{-1}\), obese versus lean mice, \(p<0.001\)). As a result, total hepatic glucose output remained unaffected (165 ± 31 vs 178 ± 28 µmol·kg\(^{-1}\)·min\(^{-1}\), obese vs lean mice, NS). The metabolic clearance rate of glucose was significantly lower in obese mice (8 ± 2 vs 18 ± 2 ml·kg\(^{-1}\)·min\(^{-1}\), obese versus lean mice, \(p<0.001\)). Hepatic mRNA levels of genes encoding for glucokinase and pyruvate kinase were markedly increased in ob/ob mice. Conclusions/interpretation Unaffected total hepatic glucose output in the presence of hyperinsulinaemia reflects hepatic insulin resistance in ob/ob mice, which is associated with markedly increased rates of glucose cycling. Hyperglycaemia in ob/ob mice primarily results from a decreased metabolic clearance rate of glucose.
Introduction

Hyperinsulinaemia and fasting hyperglycaemia are hallmarks of type 2 diabetes. Insulin resistance of peripheral organs (muscle and adipocytes), as well as of the liver, may contribute to fasting hyperglycaemia. Peripheral insulin resistance reduces the ability of peripheral organs to clear glucose from the circulation. Hepatic insulin resistance develops in two stages. During the early stages in the development of type 2 diabetes, characterised by hyperinsulinaemia and normoglycaemia, hepatic glucose production is still normal under fasting conditions. However, during absorptive phases when insulin concentrations are elevated, hepatic glucose production remains inappropriately high. At later stages in the development of type 2 diabetes in humans, hepatic glucose production starts to increase even under fasting conditions (1).

Both gluconeogenesis and glycogenolysis may contribute to elevated hepatic glucose production. Furthermore, data indicates that cycling of glucose, the process of sequential glucose uptake and subsequent phosphorylation by glucokinase and dephosphorylation by glucose-6-phosphatase (G6Pase), occurs at increased rates in humans with type 2 diabetes (2,3). Little is known about the quantitative role of glucose cycling in the increased production of hepatic glucose in type 2 diabetes. Depending on the methodologies used for quantification of hepatic glucose fluxes, increased glucose cycling may affect the estimation of rates of gluconeogenesis and glycogenolysis.

Leptin-deficient ob/ob mice suffer from severe obesity and diabetes due to leptin deficiency, and provide a model for type 2 diabetes. These mice exhibit age-dependent hyperglycaemia and hyperinsulinaemia. Quantitative data on the perturbations of glucose metabolism in these mice in vivo are scarce. In vitro studies on perfused isolated livers of ob/ob mice have shown that glycogen turnover is increased (4). In addition, glucose cycling rates have been shown to be greatly increased in hepatocytes isolated from 24-h fasted ob/ob mice (5).

Novel methodologies using multiple stable isotopes in vivo now allow the determination of flux rates through the separate metabolic pathways involved in hepatic carbohydrate metabolism (6-8). In the current study, we used these methods to evaluate the quantitative role of gluconeogenesis, glycogenolysis and glucose cycling in hyperglycaemia in modestly fasted ob/ob mice.

Experimental procedures

Animals

Female ob/ob mice (n=7) and lean littermates (n=7), 8 weeks of age and on a C57Bl/6 genetic background, were purchased from Harlan (Zeist, The Netherlands). The mice were housed in a temperature-controlled (21 °C) room with a dark–light cycle of 12 h each. Experimental procedures were approved by the Ethics Committee for Animal Experiments of the State University Groningen. Mice were fitted with a permanent catheter in the right atrium via the right jugular vein, as described previously (9). Mice were allowed to recover from surgery for at least 4 days.
Materials
The following isotopes were used: [2−13C]-glycerol (99% 13C atom percent excess), [1−2H]-galactose (98% 2H atom percent excess) (Isotec, Miamisburg, Ohio, USA), [U−13C]-glucose (99% 13C atom percent excess) (Cambridge Isotope Laboratories, Andover, Mass., USA). All chemicals used were reagent pro analysis grade. Blood spots and urine were collected on Schleicher and Schuell No. 2992 filter paper (Schleicher and Schuell, ‘s Hertogenbosch, The Netherlands). Infusates were freshly prepared and sterilised by the Hospital Pharmacy at the day before the experiment.

Animal experiments
Experiments were performed in awake, chronically catheterised mice, essentially as described previously (10). Mice were fasted for 9 h, after which they were placed in metabolic cages to allow frequent collection of blood spots and urine. Mice were infused with a sterile solution containing [U−13C]-glucose (13.9 µmol/ml), [2−13C]-glycerol (160 µmol/ml), [1−2H]-galactose (33 µmol/ml) and paracetamol (1.0 mg/ml) at a rate of 0.6 ml/h. During the experiment, blood glucose was measured using EuroFlash test strips (LifeScan Benelux, Beerse, Belgium). Blood spots were collected on filter paper before the start of the infusion and hourly afterwards until 6 h after the start of the infusion. Blood spots were air-dried and stored at room temperature until analysis. Timed urine samples were collected on filter paper strips at hourly intervals. Strips were air-dried and stored at room temperature until analysis. At the end of the experiment, animals were anaesthetised with isoflurane, and a large blood sample was collected in heparin-containing tubes by heart puncture. The sample was centrifuged immediately and stored at −20 °C until analysis. The liver was quickly excised, weighed and immediately frozen in liquid nitrogen.

Determination of metabolite concentrations
Plasma was isolated from blood by centrifugation, and liver tissue was homogenised. Commercially available kits were use to determine plasma levels of ß-hydroxybutyrate, lactate (Roche Diagnostics, Mannheim, Germany) and NEFA (Wako Chemicals, Neuss, Germany). Plasma insulin levels were determined by RIA (RI-13K; Linco Research, St. Charles, Mo., USA). Total liver protein content was determined according to the method of Lowry et al. (11). Hepatic glycogen was determined by sonication after extraction with 1 mol/l KOH. The extract was incubated at 90 °C for 30 min, cooled and then adjusted to pH 4.5 by the addition of 3 mol/l acetic acid. Precipitated protein was removed by centrifugation. Glycogen was converted to glucose by treating the samples with amyloglucosidase. A glucose assay was then performed at pH 7.4 with ATP, NADP+, hexokinase and G6P dehydrogenase.

Liver samples for the determination of G6P were treated by sonication in a 5% (w/v) HClO4 solution. Precipitated protein was removed by rapid centrifugation at 20000 g for 1 min in a cold microcentrifuge, and the supernatant was neutralised to pH 7 by the addition of small amounts of a solution containing 2 mol/l KOH and 0.3 mol/l MOPS. Levels of G6P were determined fluorimetrically with NADP+ and G6P dehydrogenase.

Hepatic mRNA levels
Total RNA was isolated from liver tissue using the Trizol method (Invitrogen, Paisley, UK). Using random primers, RNA was converted to cDNA with M-Mulv-RT (Roche Diagnostics) according to the manufacturer’s protocol. The cDNA levels of the genes of interest were measured by RT-PCR using the ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, Calif., USA). An amount of cDNA equivalent to 20 ng of total RNA was amplified using the qPCR core kit (Eurogentec, Seraing, Belgium) according to the manufacturer’s protocol with the appropriate forward and reverse primers (Invitrogen) and a
template-specific 3’-TAMRA, 5’-FAM-labelled Double Dye Oligonucleotide probe (Eurogentec). Calibration curves were run on serial dilutions of pooled cDNA solutions as used in the assay. The data were processed using the ABI Sequence Detector v.1.6.3 (Applied Biosystems). Quantified expression levels were within the linear part of the calibration curves. PCR results were normalised by 18S-rRNA levels. The sequences of the primers and probes used in this study are listed in table 2.1.

Table 2.1. Sequences of the primers and probes used in PCR measurements

<table>
<thead>
<tr>
<th>Gene</th>
<th>Sense</th>
<th>Sequence</th>
<th>GeneBank no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-actin</td>
<td>Forward</td>
<td>ACCCACACTGTGCCCATCTAC</td>
<td>NM_007393</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>GCTGGGTGATCTTCTCATGA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>AGGGCTATGCTCCCTCACGCA</td>
<td></td>
</tr>
<tr>
<td>18S-rRNA</td>
<td>Forward</td>
<td>CGGCTACCAACATCAAAGGA</td>
<td>X00686</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>CCAATTACAGGGCCTGAAGAA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>CGCGCAAAATTACCCACTCGCA</td>
<td></td>
</tr>
<tr>
<td>G6ph</td>
<td>Forward</td>
<td>CTGCAAGGGAGAACTAGCAA</td>
<td>NM_008061</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>GAGGACCAAGGAAGCCAAAT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>TGCTCGCCATTCGCTTCCA</td>
<td></td>
</tr>
<tr>
<td>G6Pt</td>
<td>Forward</td>
<td>GAGGCCTTGTAGGAAGCATTG</td>
<td>NM_008063</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>CCATCCCAGCCATCATGAGTA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>CTCTGTATGGGAACCCTGCA</td>
<td></td>
</tr>
<tr>
<td>Gk</td>
<td>Forward</td>
<td>CCTGGGGCTTCACCTTTCCTT</td>
<td>NM_010292</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>GAGGCCCTTGAAGCCCTTGTG</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>CACGAAGACATAGACAAGGGCATCCTGTC</td>
<td></td>
</tr>
<tr>
<td>Gp</td>
<td>Forward</td>
<td>GAAGGAGGCAAACGGATCAAC</td>
<td>NM_133198</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>TCACGATGCTCCGAGTGATGCT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>CCTCTGCATCGGCTGCA</td>
<td></td>
</tr>
<tr>
<td>Gs</td>
<td>Forward</td>
<td>GCTCTCCAGACGATTTTGCA</td>
<td>NM_145572</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>GTGCGGTTCCTCTGAAATGATC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>CCTCTACGGGGTTGGTAAACAGTCACGCC</td>
<td></td>
</tr>
<tr>
<td>Pk</td>
<td>Forward</td>
<td>CGTTTGTGCCACACAGATGCT</td>
<td>NM_013631</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>CATTGCCACATCCGCTTCTGT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>AGCATGATCATAAGGGCTCGACCCAACCTCG</td>
<td></td>
</tr>
<tr>
<td>Pepck</td>
<td>Forward</td>
<td>GTGTATCCCGCAAGCTGAA</td>
<td>NM_011044</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>CTTTTCGATCCTGGCGACATC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>CAACTGTGGGTGCTCCTGACCC</td>
<td></td>
</tr>
</tbody>
</table>
Mass isotopomer distribution analysis

Glucose and paracetamol-glucuronic acid (Par-GlcUA) were extracted from blood spot and urine filter paper strips respectively, derivatised, and measured by GC-MS, essentially as described previously (8,10). The fractional isotopomer distribution according to GC-MS ($m_0$–$m_6$) was corrected for the fractional distribution due to the natural abundance of $^{13}$C by multiple linear regression, as described by Lee et al. (6) to obtain the excess mole fraction of mass isotopomers $M_0$–$M_6$ due to incorporation of infused labelled compounds, i.e. [2-$^{13}$C]-glycerol, [$U^{-13}$C]-glucose and [1-$^2$H]-galactose.

Figure 2.1 shows a graphical representation of the isotopic model applied in which the following metabolic pathways are considered: (i) de novo synthesis of G6P; (ii) glycogenolysis; (iii) glucokinase; (iv) glucose-6-phosphatase; and (v) glycogen synthesis. Gluconeogenesis is represented by the combination of the pathways (i) and (iv). Glycolysis is not considered in this model. Paracetamol, [2-$^{13}$C]-glycerol, [$U^{-13}$C]-glucose and [1-$^2$H]-galactose were used to calculate flux rates through the pathways mentioned above. Paracetamol, as its glycoconjugate Par-GlcUA, was used to sample UDP-glucose. Incorporation of [2-$^{13}$C]-glycerol into blood glucose and urinary Par-GlcUA was used to estimated the fractional contributions of de novo synthesis of G6P to blood glucose and UDP-glucose (via Par-GlcUA) respectively. These fractional contributions were subsequently converted into absolute rates of gluconeogenic flux into each of the compounds by
Hepatic glucose metabolism in ob/ob mice

multiplying by the rate of appearance of blood glucose and UDP-glucose (via Par-GlcUA) respectively. The rates of appearance of blood glucose and UDP-glucose were calculated from the isotopic dilution of [U-13C]-glucose and [1-2H]-galactose in blood glucose and urinary Par-GlcUA respectively.

The whole-body blood glucose production rate [Ra(glc;whole body)], equal to blood glucose disposal [Rd(glc)] at isotopic steady-state, was calculated according to:

\[
Ra(\text{glc; whole body}) = Ra(\text{glc}) = \frac{M_6(\text{glc})_{\text{infuse}}}{M_6(\text{glc})_{\text{blood}}} \times \text{infusion(glc;M}_6) \tag{1}
\]

in which \(M_6(\text{glc})_{\text{infuse}}\) is the excess mole fraction of infused [U-13C]-glucose, \(M_6(\text{glc})_{\text{blood}}\) is the excess mole fraction of blood [U-13C]-glucose, and \(\text{infusion(glc;M}_6)\) is the infusion rate of uniformly labeled [U-13C]-glucose.

Metabolic clearance rate of blood glucose [MCR(glc)] was calculated according to:

\[
MCR(\text{glc}) = \frac{Rd(\text{glc})}{[\text{glc}]} \tag{2}
\]

where \([\text{glc}]\) is the blood glucose concentration in mmol/l.

The rates of endogenous glucose production [Ra(glc;endo)] were calculated according to:

\[
Ra(\text{glc;endo}) = Ra(\text{glc; whole body}) - \text{infusion(glc;M}_6) \tag{3}
\]

The rates of whole-body production of UDP-glucose [Ra(UDPglc;whole body)] were calculated according to:

\[
Ra(\text{UDPglc; whole body}) = M_1(\text{gal})_{\text{infuse}}/M_1(\text{Par-GlcUA}) \times \text{infusion (gal;M}_1) \tag{4}
\]

in which \(M_1(\text{gal})_{\text{infuse}}\) is the excess mole fraction of infused [1-2H]-galactose, \(M_1(\text{Par-GlcUA})\) is the excess mole fraction of urinary Par-[1-2H]-GlcUA, and \(\text{infusion(gal;M}_1)\) is the infusion rate of [1-2H]-galactose. Ra(UDPglc;whole body) was calculated assuming a constant and complete entry of infused galactose into the hepatic UDP-glucose pool. Furthermore, it was assumed that the fractional isotopomer distribution observed for Par-GlcUA reflects the fractional isotopomer distribution for UDP-glucose.

The rate of appearance of endogenously produced UDP-glucose [Ra(UDPglc;endo)] was calculated according to:

\[
Ra(\text{UDPglc;endo}) = Ra(\text{UDPglc; whole body}) - \text{infusion(gal;M}_1) \tag{5}
\]

In the isotopic model applied, stable isotopically labelled compounds, \textit{i.e.} [1-2H]-galactose and [U-13C]-glucose, were used that did not lose their labeled atom(s) upon entering metabolism. As a consequence, these compounds can re-enter the circulation (recycling), acting as an additional infusion of labeled compounds of unknown magnitude, which add to the excess mole fractions observed. This results in an underestimation of the rates of appearance of these compounds (12). The contribution of recycling should therefore be added to the calculated rates of appearance of endogenous compounds to obtain the total rates of appearance of these compounds (12). To calculate the recycling of [U-13C]-glucose and [1-2H]-galactose, two exchange factors are introduced: the fractional contribution of blood glucose to UDP-glucose formation \(c(\text{glc})\), and the fractional contribution of UDP-glucose to blood glucose \(c(\text{UDPglc})\). These two factors are calculated according to:

\[
c(\text{glc}) = M_6(\text{Par-GlcUA})/M_6(\text{glc})_{\text{blood}} \tag{6}
\]
In insulin sensitivity of hepatic glucose and lipid metabolism in animal models of hepatic steatosis

in which $M_0(\text{Par}-\text{GlcUA})$ is the excess mole fraction of urinary Par-[U-13C]-GlcUA; and

$$c(\text{UDPglc}) = M_1(\text{glc})_{\text{blood}}/M_1(\text{Par}-\text{GlcUA})$$ (7)

in which $M_1(\text{glc})_{\text{blood}}$ is the excess mole fraction of blood [$1-2^H$]-glucose. The associated rates of recycling of blood glucose [R(r(glc))] and of UDP-glucose [R(r(UDPglc))] were calculated as follows:

$$R(r(glc)) = \frac{c(glc)}{1 - c(glc)} \times Ra(glc;\text{endo})$$ (8)
$$R(r(UDPglc)) = \frac{c(UDPglc)}{1 - c(UDPglc)} \times Ra(UDPglc;\text{endo})$$ (9)

Total rates of endogenous glucose production [total Ra(glc;endo)] and endogenous UDP-glucose [total Ra(UDPglc;endo)] are calculated according to:

$$\text{total Ra(glc;endo)} = Ra(glc;\text{endo}) + R(r(glc))$$ (10)
$$\text{total Ra(UDPglc;endo)} = Ra(UDPglc;\text{endo}) + R(r(UDPglc))$$ (11)

The fractional contribution of the *de novo* synthesis of G6P to the production of glucose [f(glc)] and UDP-glucose [f(UDPglc)] was calculated from the incorporation of [2-13C]-glycerol into glucose and Par-GlcUA respectively, as described in detail elsewhere (7,8). The rates of the gluconeogenic fluxes into blood glucose [GNG(glc)] and into UDP-glucose [GNG(UDPglc)] were calculated according to:

$$\text{GNG(glc)} = f(glc) \times (\text{total Ra(glc;endo)} + \text{infusion(glc;M}_6)$$ (12)
$$\text{GNG(UDPglc)} = f(UDPglc) \times (\text{total Ra(UDPglc;endo)} + \text{infusion(gal;M}_1)$$ (13)

The *de novo* synthesis of G6P [GNG(G6P)] is the sum of GNG(glc) and GNG(UDPglc), corrected for the exchange of label between blood glucose and UDP-glucose, calculated according to:

$$\text{GNG(G6P)} = \text{GNG(glc)} \times (1 - c(UDPglc)) + \text{GNG(UDPglc)} \times (1 - c(glc))$$ (14)

The contribution of glycogenolysis to blood glucose formation [GLY(glc)] and UDP-glucose formation [GLY(UDPglc)] was calculated according to:

$$\text{GLY(glc)} = \text{total Ra(glc;endo)} - \text{GNG(glc)}$$ (15)

in which the contribution of glycogenolysis to the total rate of appearance of glucose in blood is equal to the part that is not derived from gluconeogenesis; and

$$\text{GLY(UDPglc)} = \text{total Ra(UDPglc;endo)} - \text{GNG(UDPglc)} - \text{glc(UDPglc)}$$ (16)

in which glc(UDPglc) represents the contribution of blood glucose to UDP-glucose, which was calculated according to:

$$\text{glc(UDPglc)} = c(glc) \times (\text{total Ra(UDPglc;endo)} + \text{infusion(gal;M}_1))$$ (17)
In contrast to blood glucose, the total rate of appearance of UDP-glucose is determined by: (i) gluconeogenic flux from G6P; (ii) glycogenolysis; and (iii) the flux of blood glucose into the UDP-glucose pool. The flux of glycogen into UDP-glucose is a measure of glycogen/glucose-1-phosphate cycling (8).

The individual isotopic fluxes through the various enzymes involved in hepatic glucose metabolism were calculated based on a factorial model by adding the different contributions to the flux rates. For the enzymes glucokinase (Gk), glucose-6-phosphatase (G6pase), glycogen synthase (Gs) and glycogen phosphorylase (Gp) the flux rates were calculated according to:

\[ Gk = \text{glc}(\text{UDPglc}) + \text{R}(r(\text{glc})) \]  \hspace{1cm} (18)

in which only two contributions to the flux through Gk are considered (i.e. the flux of blood glucose into UDP-glucose and glucose / G6P cycling), whereas glycolysis is not included.

\[ \text{G6pase} = \text{total Ra}(\text{glc};\text{endo}) = \text{GNG}(\text{glc}) + \text{GLY}(\text{glc}) \]  \hspace{1cm} (19)
\[ \text{Gs} = \text{Ra}(\text{UDPglc};\text{whole body}) \]  \hspace{1cm} (20)
\[ \text{Gp} = \text{GLY}(\text{glc}) + \text{GLY}(\text{UDPglc}) \]  \hspace{1cm} (21)

in which two contributions to the flux through glycogen phosphorylase are considered (i.e. glycogenolysis resulting in blood glucose appearance and glycogen/G1P cycling).

**Statistical analysis**

All values are means ± SD. Levels of significance of difference of metabolite concentrations, gene expression and the values of the individual time points during isotope infusion experiments were determined using the non-parametric Mann–Whitney test for unpaired data. Levels of significance of differences between the averages of the values of the fluxes at individual time points between 3 and 6 h during the experiment were estimated using repeated measures ANOVA. A p-value of less than 0.05 was considered statistically significant.

**Results**

Body and liver weights of obese mice were more than double those of lean mice (table 2.2). Consequently, normalisation of liver weight to body weight yielded no difference between obese and lean mice. Protein contents per gram of liver tissue were not significantly different between obese and lean mice. Hepatic glycogen content was mildly elevated in ob/ob mice, whereas G6P levels were not significantly different between the two groups. At the end of the experiment, plasma NEFA concentrations were almost two-fold higher in ob/ob mice than in the lean mice. Plasma lactate and alanine concentrations were similar in the two groups, whereas plasma ß-hydroxybutyrate concentrations were elevated in ob/ob mice.

Figure 2.2 shows the blood glucose concentrations of the two groups of mice during the infusion experiment. Obese mice were clearly hyperglycaemic (8.8 ± 0.5 vs. 13.2 ± 1.9 mmol/l, lean versus obese mice, p<0.05) and hyperinsulinaemic. Insulin concentrations remained constant (45 ± 10 pmol/l at t=0 and 60 ± 45 pmol/l at t=6 h) during the experiment in lean mice, but decreased from 900 ± 480 pmol/l at t=0 to 435 ± 270 pmol/l at t=6 h in ob/ob mice.
Table 2.2. Hepatic and plasma parameters in ob/ob mice and lean littermates

<table>
<thead>
<tr>
<th></th>
<th>Lean mice (n=7)</th>
<th>Ob/ob mice (n=7)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Liver</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>body weight (g)</td>
<td>22.7 ± 1.2</td>
<td>49.7 ± 3.0 *</td>
</tr>
<tr>
<td>liver weight (g)</td>
<td>1.1 ± 0.0</td>
<td>2.6 ± 0.4 *</td>
</tr>
<tr>
<td>relative liver weight (% body weight)</td>
<td>4.7 ± 0.3</td>
<td>5.0 ± 0.8</td>
</tr>
<tr>
<td>total liver protein (mg)</td>
<td>156 ± 20</td>
<td>325 ± 63 *</td>
</tr>
<tr>
<td>liver protein content (mg/g liver)</td>
<td>144 ± 18</td>
<td>127 ± 18</td>
</tr>
<tr>
<td>G6P (nmol/g liver)</td>
<td>118 ± 56</td>
<td>153 ± 34</td>
</tr>
<tr>
<td>glycogen (µmol glucose/g liver)</td>
<td>179 ± 16</td>
<td>207 ± 11 *</td>
</tr>
<tr>
<td><strong>Plasma</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>glucose (mmol/l)</td>
<td>8.8 ± 0.5</td>
<td>13.2 ± 1.9 *</td>
</tr>
<tr>
<td>insulin (pmol/l)</td>
<td>45 ± 10</td>
<td>900 ± 480 *</td>
</tr>
<tr>
<td>NEFA (mmol/l)</td>
<td>0.5 ± 0.1</td>
<td>0.9 ± 0.2 *</td>
</tr>
<tr>
<td>β-hydroxybutyrate (mmol/l)</td>
<td>0.5 ± 0.4</td>
<td>3.1 ± 1.4 *</td>
</tr>
<tr>
<td>alanine (µmol/l)</td>
<td>133 ± 113</td>
<td>176 ± 33</td>
</tr>
<tr>
<td>lactate (mmol/l)</td>
<td>3.5 ± 1.0</td>
<td>3.5 ± 1.0</td>
</tr>
</tbody>
</table>

Figure 2.3 shows endogenous glucose production [Ra(glc;endo), equation (3)] and the metabolic clearance rate of glucose [MCR(glc), equation (2)]. At isotopic steady-state, i.e. between 3 h and 6 h after the start of the infusion of labelled compounds, endogenous glucose production was significantly decreased in ob/ob mice (152 ± 27 vs. 109 ± 23 µmol·kg⁻¹·min⁻¹, lean versus obese mice, p<0.001), as was the metabolic clearance rate of glucose (18 ± 2 vs. 8 ± 2 ml·kg⁻¹·min⁻¹, lean versus obese mice, p<0.001).

The rate of de novo synthesis of G6P [GNG(G6P), equation (14)] in obese mice was significantly lower than that in lean control mice (160 ± 6 vs. 122 ± 13 µmol·kg⁻¹·min⁻¹, lean versus obese mice, p<0.001) (figure 2.4a). In obese mice, the partitioning of newly synthesised G6P towards plasma glucose or glycogen was similar to that in lean control mice (figure 2.4b). In contrast, glucose cycling [R(r(glc)), equation (8)] was greatly enhanced in obese mice (56 ± 13 µmol·kg⁻¹·min⁻¹ vs. 26 ± 4 µmol·kg⁻¹·min⁻¹, obese versus lean mice, p<0.001) (figure 2.5a). Consequently, total endogenous glucose production, i.e. the sum of endogenous glucose production and glucose cycling, was not significantly different in obese and lean mice (178 ± 28 vs. 165 ± 31 µmol·kg⁻¹·min⁻¹, lean versus obese mice, NS) (figure 2.5b).

Figure 2.6 shows the calculated mean values obtained at steady-state for the individual fluxes through the various pathways of hepatic glucose metabolism. As anticipated, the calculated isotopic flux through glucokinase [Gk, equation (18)] was strongly increased in obese mice. The glucose-6-phosphatase flux [G6pase, equation (19)], equivalent to the total endogenous glucose production, was unchanged. The flux through glycogen phosphorylase [Gp, equation (21)] was not altered significantly, whereas the glycogen synthase flux [Gs, equation (20)] was significantly decreased in obese mice compared with lean littermates.

Table 2.3 provides a summary of the calculated flux rates, normalised to either body weight or amount of liver protein (liver is the major glucose-producing organ). Independent of the method of normalisation, the same conclusions can be drawn with respect to the changes in glucose metabolism in lean and ob/ob mice.
Figure 2.2. Plasma glucose concentrations during infusion experiments. Blood glucose levels in lean (empty circles, n=7) and ob/ob (filled circles, n=7) mice. Values shown are the means ± SD. * p<0.05 vs lean animals.

Figure 2.3. Endogenous glucose production (a) and metabolic clearance (b) during the infusion experiments in lean (empty circles, n=7) and ob/ob (filled circles, n=7) mice. Values shown are the means ± SD. * p<0.05 vs lean animals.
Levels of expression of relevant genes in the liver of lean and ob/ob mice are shown in figure 2.7. The expression of the genes encoding glucokinase and liver-type pyruvate kinase were strongly up-regulated in the liver of ob/ob mice. The mRNA levels of other key enzymes involved in carbohydrate metabolism (i.e. phosphoenolpyruvate carboxykinase, G6P hydrolase and G6P translocase) did not differ significantly between obese and lean mice. It has previously been shown that the expression of the genes encoding sterol regulatory element-binding protein-1c (Srebp-1c) and peroxisome proliferator-activated receptor-γ (Pparγ), transcription factors involved in control of hepatic glucose and fat metabolism, is significantly elevated in the liver of ob/ob mice compared with that of their lean littermates (13). Furthermore, mRNA levels of Irs-1, but particularly Irs-2, were observed to be strongly repressed in the liver of obese mice (13).

Figure 2.4. (a) The rate of de novo synthesis of G6P in lean (empty circles) and ob/ob (filled circles) mice. (b) The partitioning of the rates of de novo synthesis of G6P to UDP-glucose (shaded area) and to glucose (white area) during the last 3 h of the infusion experiment in lean and ob/ob mice. Values shown are the means ± SD (n=7 for each group). * p<0.05 vs. lean animals.
Table 2.3. Summary of the calculated values of the various flux rates, using the isotopic model shown in figure 2.1 normalised to either body weight or liver protein.

<table>
<thead>
<tr>
<th></th>
<th>Normalised to body weight</th>
<th>Normalised to liver protein</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normalised to body weight</td>
<td>Normalised to liver protein</td>
</tr>
<tr>
<td></td>
<td>(µmol·kg⁻¹·min⁻¹)</td>
<td>(µmol·g protein⁻¹·min⁻¹)</td>
</tr>
<tr>
<td><strong>De novo synthesis of G6P (Pepck)</strong></td>
<td>160 ± 6</td>
<td>23.6 ± 0.9</td>
</tr>
<tr>
<td></td>
<td>122 ± 13 *</td>
<td>18.8 ± 2.0 *</td>
</tr>
<tr>
<td><strong>Endogenous glucose production</strong></td>
<td>157 ± 27</td>
<td>23.1 ± 4.0</td>
</tr>
<tr>
<td></td>
<td>109 ± 23 *</td>
<td>16.8 ± 3.5 *</td>
</tr>
<tr>
<td><strong>Glucose cycling</strong></td>
<td>26 ± 4</td>
<td>3.8 ± 0.6</td>
</tr>
<tr>
<td></td>
<td>56 ± 13 *</td>
<td>8.6 ± 2.0 *</td>
</tr>
<tr>
<td><strong>Total endogenous glucose production (G6Pase)</strong></td>
<td>178 ± 28</td>
<td>26.2 ± 4.1</td>
</tr>
<tr>
<td></td>
<td>165 ± 31</td>
<td>25.4 ± 4.8</td>
</tr>
<tr>
<td><strong>Glucokinase</strong></td>
<td>73 ± 11</td>
<td>6.3 ± 1.6</td>
</tr>
<tr>
<td></td>
<td>82 ± 18 *</td>
<td>12.6 ± 2.8 *</td>
</tr>
<tr>
<td><strong>Glycogen synthase</strong></td>
<td>100 ± 35</td>
<td>14.7 ± 5.2</td>
</tr>
<tr>
<td></td>
<td>67 ± 16 *</td>
<td>10.3 ± 2.5 *</td>
</tr>
<tr>
<td><strong>Glycogen phosphorylase</strong></td>
<td>40 ± 18</td>
<td>5.9 ± 2.7</td>
</tr>
<tr>
<td></td>
<td>50 ± 15</td>
<td>7.7 ± 2.3</td>
</tr>
</tbody>
</table>

Figure 2.5. (a) Rate of cycling between glucose and G6P during the infusion experiment in lean (empty circles) and ob/ob (filled circles) mice. (b) The contributions of endogenous glucose production (white area) and glucose cycling (shaded area) to the total endogenous glucose production in lean and ob/ob mice during the last 3 h of the infusion experiment. Values shown are the means ± SD (n=7 for each group). * p<0.05 vs lean animals.
Discussion

The leptin-deficient ob/ob mouse is a commonly used mouse model of type 2 diabetes, but quantitative in vivo data on the disturbances that underlie hyperglycaemia in this model are sparse. In this study, we determined flux rates through various pathways relevant in hepatic carbohydrate metabolism in lean and ob/ob mice. When expressed per unit of body weight or liver protein, hepatic glucose metabolism activity was, in general, suppressed in obese mice compared with that in their lean littermates. However, glucose cycling was an exception to this, and was observed to be greatly increased in obese mice. Interestingly, the newly produced G6P was not preferentially directed towards plasma glucose in ob/ob mice, but instead was partitioned to glycogen stores to a similar extent as that observed in lean mice. Furthermore, the expression of genes of key enzymes involved in glucose metabolism were similar in livers of ob/ob and lean mice, apart from the expression of glucokinase and liver-type pyruvate kinase which was increased in the liver of ob/ob mice.

![Diagram of glucose metabolism pathways](image-url)

Figure 2.6. Separate fluxes through the relevant metabolic pathways involved in hepatic carbohydrate metabolism during the last 3 h of the infusion experiment in lean and ob/ob mice. Values shown are the means ± SD (n=7 for each group). * p<0.05 vs lean animals.
Before discussing the results, some methodological issues have to be addressed. In this study, a multiple isotope infusion protocol was used to calculate the relevant fluxes of glucose metabolism (7). The validity of the isotope model, with the application of glycoconjugates, and the mass isotope distribution analysis (MIDA) approach has been substantiated in various studies, although some controversy still remains (14,15). Since the contribution of glycolysis to intracellular G6P metabolism has not been included in this model, the calculated flux rate through glucokinase represents a minimal estimate. We have validated the application of MIDA in 9-h fasted C57Bl/6 mice in a separate study (10). In 24-h fasted mice, no stable isotopic steady-state could be obtained (10). In the current study, we compared hepatic glucose metabolism in groups of mice with strongly different body compositions. Our data show that, with respect to hepatic glucose metabolism, normalisation to body weight appeared to be appropriate, since the same conclusions could be drawn regardless of whether the data was normalised to body weight or liver protein.

Irrespective of hyperinsulinaemia and hyperglycaemia, total glucose output (glucose-6-phosphatase flux) was not affected, while endogenous glucose production was only modestly inhibited in ob/ob mice. This points to hepatic insulin resistance. Previously reported values of endogenous glucose production in C57Bl/6 mice are almost identical to those reported in this study in lean littermates of ob/ob mice (16,17). Furthermore, endogenous glucose production in C57Bl/6 mice could be suppressed almost completely during hyperinsulinaemic clamp at normal or increased glucose concentrations (16-18). The impaired suppression of endogenous glucose production was mainly due to the blunted response of de novo synthesis of G6P to the combined hyperinsulinaemia and hyperglycaemia in ob/ob mice. This indicates that, in the absence of leptin, insulin appears to be largely ineffective in suppressing hepatic de novo synthesis of G6P by an as yet unknown mechanism.
In the liver of ob/ob mice, the decreased contribution of endogenous glucose production to total glucose output appeared to be compensated by enhanced glucose cycling. Glucose cycling was increased by a factor of ~2.5 in the liver of ob/ob mice, due to an enhanced flux through glucokinase. A previous study reported a high rate of glucose cycling in hepatocytes isolated from the liver of ob/ob mice fasted for 24 h (5). Similarly, in an earlier publication, glucokinase activity was found to remain elevated in the liver of ob/ob mice throughout a 48-h fast (19). Collectively, these observations indicate that, independent of the duration of fasting, the liver of ob/ob mice maintains a high capacity to phosphorylate glucose.

Besides hepatic insulin resistance, peripheral organs were also found to be insulin resistant in ob/ob mice. Metabolic clearance of plasma glucose was decreased by a factor of ~2 at blood glucose concentrations that were almost double that in lean mice. This indicates that net glucose uptake by peripheral tissue was similar in ob/ob and lean mice, irrespective of the elevated insulin concentrations in the obese group. Thus, hyperglycaemia in ob/ob mice is due to peripheral insulin resistance. This finding is in agreement with an earlier study using different means to investigate peripheral insulin resistance in ob/ob mice, which reported that uptake of 2-deoxyglucose was severely inhibited in isolated skeletal muscle of obese mice compared with that in lean mice (20).

As discussed, we observed ‘normal’ rates of total glucose output and high rates of glucose cycling. In accordance with these observations, ‘normal’ mRNA levels of the gluconeogenic enzymes G6P hydrolase and phosphoenolpyruvate carboxykinase were observed, while mRNA levels of glucokinase and liver-type pyruvate kinase were significantly increased in the liver of obese mice compared to those in liver of lean littermates. Significant increases in mRNA levels of Srebp-1c and its target genes in lipogenesis, i.e. Fas and Acc1, in livers of fasted ob/ob mice have previously been reported (13,21). This indicates an enhanced glycolytic flux into lipogenesis. It should be realised that the glycolytic flux as part of the glucokinase flux cannot be assessed in the isotopic model applied. Recent data indicate that hyperglycaemia could directly induce increased expression of the genes encoding Srebp-1c and pyruvate kinase in an insulin-independent way (22).

In humans with type 2 diabetes, there is evidence for enhanced gluconeogenesis and glycogenolysis after an overnight fast, particularly in patients with severe fasting hyperglycaemia (1,23-28). Although liver was insulin resistant in ob/ob mice, this did not result in enhanced hepatic glucose production. In the present study, only a moderate fasting hyperglycaemia was observed in ob/ob mice at 8 weeks of age. Apparently, in these mice the disease had not yet progressed to a more severe stage with (very) high fasting blood glucose concentrations. Furthermore, in most studies on (often obese) diabetic subjects, the data was normalised to lean body mass instead of body weight, which might have led to seemingly elevated values for gluconeogenic and glycogenolytic fluxes in these individuals compared with those in non-diabetic subjects. Until now, only very few studies have considered the role of glucose cycling in hepatic glucose production. There are indications that hepatic cycling of glucose is elevated in humans with type 2 diabetes (2,3).

In conclusion, this study demonstrates that in ob/ob mice, de novo synthesis of G6P is diminished while glucose cycling is increased, resulting in an unaffected total glucose output by the liver. However, these observations were made where there was a background of hyperglycaemia and hyperinsulinaemia. This points to a co-existence of hepatic and peripheral insulin resistance, with peripheral insulin resistance as the cause of hyperglycaemia.
Acknowledgements

This work was supported by the Dutch Diabetes Foundation (grant 96.604). R.H.J. Bandsma is supported by the Dutch Organisation for Scientific Research (NWO). We thank T. Boer, P. Modderman and T. Jager for excellent technical assistance.

References

13. Wiegman CH, Bandsma RHJ, Ouwens M et al. (2003) Hepatic VLDL production in ob/ob mice is not stimulated by massive de novo lipogenesis but is less sensitive to the suppressive effects of insulin. Diabetes 52:1081–1089